Skip to main
RLAY
RLAY logo

RLAY Stock Forecast & Price Target

RLAY Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 57%
Buy 36%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Relay Therapeutics Inc. is leveraging its innovative Dynamo platform, which effectively combines computational and experimental techniques for drug discovery, focusing on precision oncology and genetic diseases. Recent clinical data indicate significant improvements in objective response rates (ORR) and progression-free survival (mPFS) among patients with kinase mutations, particularly with the RLY-2608 product candidate, which demonstrates enhanced tolerability and durability in treatment outcomes for breast cancer patients. With a robust cash position of $781 million earmarked for funding ongoing trials, Relay Therapeutics is well-positioned to advance its pipeline toward potentially impactful therapeutic developments, thus fostering a positive outlook for the company's stock.

Bears say

Relay Therapeutics Inc. is projected to face significant financial challenges, with anticipated losses of $2.15 per share in 2025, following a net loss of $2.36 per share in 2024. Key risks contributing to the negative outlook include potential negative clinical trial results, delays in development timelines, and hurdles in obtaining regulatory approvals, all of which could adversely affect the company's ability to generate revenue and secure market success. Additionally, the competitive landscape poses threats with therapies exhibiting safety limitations and the possibility of medium- to long-term dilution risks further exacerbating financial instability.

RLAY has been analyzed by 14 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 36% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Relay Therapeutics, Inc. (RLAY) Forecast

Analysts have given RLAY a Buy based on their latest research and market trends.

According to 14 analysts, RLAY has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Relay Therapeutics, Inc. (RLAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.